Guardant Health, Inc. Common Stock (GH)
Guardant Health, Inc. is a precision oncology company that develops blood tests for cancer detection and management. Founded in 2012, it focuses on liquid biopsy technologies to provide non-invasive cancer diagnostics, monitoring, and treatment guidance. The company's products are used for early detection, treatment selection, and tracking disease progression in various types of cancer.
Company News
The global liquid biopsy market is projected to grow from $4.03 billion in 2025 to $7.05 billion by 2030, driven by rising cancer incidence, precision medicine advancements, and technological innovations in early disease detection.
Guardant Health reported strong Q2 2025 financial results, with revenue of $232.1 million (31% YoY growth), beating analyst estimates. The company saw significant progress in its oncology diagnostics and Shield screening business, raising full-year guidance to $915-$925 million.
Guardant Health and Pfizer have announced a strategic collaboration to use Guardant's liquid biopsy platform in Pfizer's oncology clinical trials, including monitoring circulating tumor DNA as a therapy response marker. The collaboration will also allow Pfizer to access Guardant's liquid biopsy tests in China.
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
